Engineered cancer-killing viruses plus immune-boosting drugs for glioblastoma
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
An engineered virus given with drugs that lift immune suppression aims to help people with glioblastoma fight their tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11212005 on NIH RePORTER |
What this research studies
Researchers are building on an engineered adenovirus that has already produced long-term responses in some patients with recurrent glioblastoma. They are arming the virus to better activate T cells and combining it with drugs that block tumor immune-suppression pathways such as IDO. The work uses preclinical models and translational studies to optimize the virus and the drug combination before bringing it into patients. The team at MD Anderson plans this pathway to improve how well virotherapy works against aggressive brain tumors.
Who could benefit from this research
Good fit: Ideal candidates would be people with glioblastoma (often recurrent) who meet clinical-trial criteria and can undergo delivery of the virus at a participating center.
Not a fit: People with other brain tumor types, severe immune suppression, or those unable to receive intratumoral or surgical delivery may not benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could shrink tumors and improve long-term survival for some people with glioblastoma.
How similar studies have performed: A prior phase I trial of the same oncolytic adenovirus showed durable responses in about 20% of recurrent GBM patients, but combining the virus with immune-metabolism drugs is a newer and still experimental strategy.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Fueyo, Juan — University of Tx Md Anderson Can Ctr
- Study coordinator: Fueyo, Juan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.